(MENAFN- Trend News Agency)
Use of Pfizer Inc's (PFE.N) COVID-19 antiviral Paxlovid spiked
this week, but some doctors are reconsidering the pills for
lower-risk patients after a U.S. public health agency warned that
symptoms can recur after people complete a course of the drug, and
that they should then isolate a second time, Trend reports citing Reuters .
More quarantine time 'is not a crowd-pleaser,' Dr. Sandra
Kemmerly, an infectious disease specialist at Ochsner Health in New
Orleans, told Reuters. 'For those people who really aren't at risk
... I would recommend that they not take it.'
Use of Pfizer's Paxlovid, authorized to treat newly infected,
at-risk people in order to prevent severe illness, has soared as
infections have risen. More than 162,000 courses were dispensed
last week - compared with an average of 33,000 a week since the
drug was launched late last year, according to government data.
Biden administration officials have pushed for wide use of
Paxlovid, which the government purchased and provides free.
But higher use has also come with more reports from people who
say their symptoms eased with Paxlovid only to return a few days
after finishing a five-day regimen of the pills.
Tags:
- US
- coronavirus COVID-19
- Pfizer
MENAFN28052022000187011040ID1104285506
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.